The actions of the ingredients contained in NurAiD™ II (MLC901) are described in more than 50 publications and works by International University and Research Institutes.
Research developments in the field of neurosciences for understanding the complexity of the brain are continuous and exciting.
Clinical studies have shown that the administration of NurAiD™ II (MLC901) supports the increase of BDNF (Brain-Derived Neurotrophic Factor)1,2, a neurotrophic protein that plays a regulatory role in the development, differentiation and survival of nerve cells and in the ability of the brain to develop, change and adapt (neuroplasticity).
The combination of nature and science starts with the raw material. Applying modern production methods, NurAiD™ II (MLC901) is manufactured in accordance with recognized principles and international standards of good manufacturing practice (GMP).
The recommended standard dosage regimen is 2 capsules in the morning, at noon, and in the evening, while it is recommended to start treatment early in the first stages of recovery and for at least three months.
Regarding the administration of NurAiD™ II (MLC901), consumers are encouraged to seek medical guidance.
It is taken alongside medication and for at least 3 months.
The capsules can be opened and the contents diluted in water or administered via a gastric tube.
Do not exceed the recommended daily dose.
